Alvotech is furthering efforts to have a debt facility in place worth up to $125m as it kicks off life as a public company, amid challenging global market conditions.
Alvotech expects to have its backstop debt facility worth up to $125m in place by the end of the year, after conceding that higher-than-expected shareholder redemptions and “unexpected global market conditions” have delayed the process.
The Icelandic firm, which became a public company in June following its merger with a special purpose acquisition company, Oaktree...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
